Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin in Fatty Liver Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided written informed consent prior to screening~* Men and women aged 18-70 years~* With non-alcoholic steatohepatitis histologically-proven, as evidenced by the presence of all of: steatosis, hepatocyte ballooning and lobular inflammation, and scored according to Kleiner(18) by a single experienced histopathologist (RDG) within the previous year, with or without mild to moderate fibrosis (stage 0-3/4)~* With persistently elevated alanine aminotransferase (ALT) values on at least two occasions in the three months prior to recruitment~Exclusion Criteria:~* NAFLD with cirrhosis (fibrosis score 4)~* Other causes of chronic liver disease~  * Viral hepatitis (HBV, HCV negative)~ * Alcohol intake \>14units/week (women) or \>21units/week (men)~ * Haemachromatosis (abnormal transferrin saturation, haemochromatosis genotyping)~* Evidence of hepatic decompensation~  * Ascites~ * Hepatic encephalopathy~ * Abnormal total bilirubin (except patients with Gilbert's syndrome), albumin, prolonged prothrombin time, low platelets)~ * Oesophageal or gastric varices~* Moderate or severe renal dysfunction (CKD3+, estimated GFR \<60ml/min/1.73m2)~* Hepatocellular carcinoma~* Primary metabolic causes of hepatic steatosis (e.g. familial hypertriglyceridaemia, abetalipoproteinaemia)~* Other malignancy~* Pregnant or lactating women or women of childbearing potential unwilling/unable to use adequate contraceptive methods~* Systemic inflammatory conditions~  * Arthritis~ * Connective tissue disorders~ * Inflammatory bowel disease~* Myocardial infarction within 6 months~* Stroke within 6 months~* Bariatric surgery/ blind loop/ short bowel~* Treatment known/suspected to change gut flora (e.g. systemic antibiotics, colestyramine, lactulose, polyethylene glycol) within 3 months~* Treatment with drugs known to cause hepatic steatosis (e.g. corticosteroids, HAART, amiodarone, high dose oestrogens, tamoxifen) within 3 months~* Initiation or major dose change of metformin, thiazolidinediones, biguanides, statins, fibrates, anti-obesity medications or insulin within 3 months of enrolment~* Patients with allergy to Rifaximin or Rifamycin~* Patients with a cardiac pacemaker, history of penetrating eye injury, metal foreign body or any other contra-indication to MRI scanning, as specified in the local MRI safety checklist~* Any other clinical, social or psychological issues which, in the opinion of the investigators may preclude satisfactory completion of the study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rifaximin for 6-weeks followed by 6-week observation period (Type: EXPERIMENTAL): All patients receiving 6 weeks Rifaximin 400mg twice daily, followed by a 6 week observation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).